Viatris
Biosimilar developer, United States. 2 development products across 2 molecules: bevacizumab, darbepoetin alfa.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Bevacizumab | Lextemy | · | withdrawn | · | · | · | · | · | 0/7 |
| Darbepoetin alfa | Darbepoetin Alfa BS MYL | · | · | · | Sep 2019 | · | · | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which Viatris is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Etanercept | Mylan Pharmaceuticals Private (INN only) | CDSCO | Mylan Pharmaceuticals Private Limited, now Biocon Biologics Limited | Jan 2021 | Lupin |
In development
ClinicalTrials.gov lists two comparative trials sponsored by Viatris for one molecule: adalimumab. Candidates without an approval yet in the seven markets: BMO-2.
| Molecule | Candidate | Developer or sponsor | Reference product | Phase | Design | Registry status | Started | Primary completion | In the Atlas | Registry record |
|---|---|---|---|---|---|---|---|---|---|---|
| Adalimumab | BMO-2 | Viatris | Humira | Phase 1 | Comparative PK | Completed | Dec 2014 | May 2015 | no approval in the seven markets | NCT02472912 |
| Adalimumab | MYL-1401A | Viatris | Humira | Phase 3 | Comparative efficacy | Completed | Jun 2015 | May 2016 | Hulio | NCT02714322 |
Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.
Companies on the same molecules
Developers whose portfolios overlap most with Viatris, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- PMDASep 2019Darbepoetin Alfa BS MYL, darbepoetin alfa
Compare Viatris with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant